Singh Aastha, Sen Dwaipayan
Cellular and Molecular Therapeutics Laboratory, Centre for Biomaterials, Cellular and Molecular Theranostics (CBCMT), VIT University, Vellore -632014, Tamil Nadu, India.
Curr Gene Ther. 2016;16(4):278-286. doi: 10.2174/1566523216666160729113558.
Although adeno-associated viral vectors have been studied for a long time, its importance as a viable gene therapy strategy has been thrusted into the limelight only in the recent years. Due to the admirable characteristics of these vectors, their potential has been thoughtfully utilized in the treatment of several neurodegenerative diseases. This mini-review focuses at recapitulating the therapeutic advances of adeno-associated viral vectors in the treatment of Parkinson's disease by studying the various animal model experiments and clinical trials conducted since the advent of adeno-associated viral vector - based gene therapy. Additionally, the chronological analysis of the studies in the review makes it easier to understand the challenges and foretell the future prospects in this field of therapeutics.
尽管腺相关病毒载体已经被研究了很长时间,但直到最近几年,其作为一种可行的基因治疗策略的重要性才受到关注。由于这些载体具有令人钦佩的特性,它们的潜力已被深入用于远见地应用于多种神经退行性疾病的治疗。本综述通过研究自基于腺相关病毒载体的基因治疗问世以来进行的各种动物模型实验和临床试验,重点阐述了腺相关病毒载体在帕金森病治疗中的治疗进展。此外,综述中对研究的按时间顺序分析使得更容易理解该治疗领域的挑战并预测未来前景。